Rat indwelling urinary catheter model of Candida albicans biofilm infection

Infection and Immunity

Volumn 82, Issue 12, 2014, Pages 4931-4940

  Nett, Jeniel E ^a,b   Brooks, Erin G ^a   Cabezas Olcoz, Jonathan ^a   Sanchez, Hiram ^a   Zarnowski, Robert ^a   Marchillo, Karen ^a,b   Andes, David R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BIOFILM; BLADDER WALL; CANDIDIASIS; CANDIDURIA; CATHETER INFECTION; CONTROLLED STUDY; CYSTITIS; EXTRACELLULAR MATRIX; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INDWELLING URINARY CATHETER; NONHUMAN; PHENOTYPE; PYURIA; RAT; RODENT MODEL; ANIMAL; CANDIDA ALBICANS; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; INDWELLING CATHETER; MICROBIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; URINARY CATHETER;

ANIMALS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; CATHETERS, INDWELLING; CYSTITIS; DISEASE MODELS, ANIMAL; FEMALE; PYURIA; RATS, SPRAGUE-DAWLEY; URINARY CATHETERS;

EID: 84911407075     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02284-14     Document Type: Article

References (65)

1. Stamm WE. 1991. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am. J. Med. 91:65S-71S. http://dx.doi.org/10.1016/0002-9343(91)90345-X.
2. Tambyah PA, Knasinski V, Maki DG. 2002. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect. Control Hosp. Epidemiol. 23:27-31. http://dx.doi.org/10.1086/501964.
3. Richards MJ, Edwards JR, Culver DH, Gaynes RP. 1999. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 27:887-892. http://dx.doi.org/10.1086/501795.
4. Bouza E, San Juan R, Munoz P, Voss A, Kluytmans J, Co-operative Group of the European Study Group on Nosocomial Infections. 2001. A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections. Clin. Microbiol. Infect. 7:523-531. http://dx.doi.org/10.1046/j.1198-743x.2001.00326.x.
5. Achkar JM, Fries BC. 2010. Candida infections of the genitourinary tract. Clin. Microbiol. Rev. 23:253-273. http://dx.doi.org/10.1128/CMR.00076-09.
6. Kauffman CA. 2014. Diagnosis and management of fungal urinary tract infection. Infect. Dis. Clin. North Am. 28:61-74. http://dx.doi.org/10.1016/j.idc.2013.09.004.
7. Saint S, Wiese J, Amory JK, Bernstein ML, Patel UD, Zemencuk JK, Bernstein SJ, Lipsky BA, Hofer TP. 2000. Are physicians aware of which of their patients have indwelling urinary catheters? Am. J. Med. 109:476-480. http://dx.doi.org/10.1016/S0002-9343(00)00531-3.
8. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394. http://dx.doi.org/10.1128/JB.183.18.5385-5394.2001.
9. Hawser SP, Douglas LJ. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62:915-921.
10. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310. http://dx.doi.org/10.1038/nature02122.
11. O'Toole GA. 2003. To build a biofilm. J. Bacteriol. 185:2687-2689. http://dx.doi.org/10.1128/JB.185.9.2687-2689.2003.
12. Katragkou A, Simitsopoulou M, Chatzimoschou A, Georgiadou E, Walsh TJ, Roilides E. 2011. Effects of interferon-gamma and granulocyte colony-stimulating factor on antifungal activity of human polymorphonuclear neutrophils against Candida albicans grown as biofilms or planktonic cells. Cytokine 55:330-334. http://dx.doi.org/10.1016/j.cyto.2011.05.007.
13. Kauffman CA, Fisher JF, Sobel JD, Newman CA. 2011. Candida urinary tract infections-diagnosis. Clin. Infect. Dis. 52(Suppl 6):S452-S456.
14. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
15. Maki DG, Tambyah PA. 2001. Engineering out the risk for infection with urinary catheters. Emerg. Infect. Dis. 7:342-347. http://dx.doi.org/10.3201/eid0702.010240.
16. Helbig S, Achkar JM, Jain N, Wang X, Gialanella P, Levi M, Fries BC. 2013. Diagnosis and inflammatory response of patients with candiduria. Mycoses 56:61-69. http://dx.doi.org/10.1111/j.1439-0507.2012.02201.x.
17. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-6031. http://dx.doi.org/10.1128/IAI.72.10.6023-6031.2004.
18. Nobile CJ, Schneider HA, Nett JE, Sheppard DC, Filler SG, Andes DR, Mitchell AP. 2008. Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 18:1017-1024. http://dx.doi.org/10.1016/j.cub.2008.06.034.
19. Andes D, van Ogtrop M. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
20. Jensen J, Warner T, Johnson C, Balish E. 1996. Oral immunization of mice against candidiasis. J. Infect. Dis. 174:133-140. http://dx.doi.org/10.1093/infdis/174.1.133.
21. Taff HT, Nett JE, Zarnowski R, Ross KM, Sanchez H, Cain MT, Hamaker J, Mitchell AP, Andes DR. 2012. A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. PLoS Pathog. 8:e1002848. http://dx.doi.org/10.1371/journal.ppat.1002848.
22. Nett JE, Sanchez H, Cain MT, Andes DR. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202:171-175. http://dx.doi.org/10.1086/651200.
23. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262.
24. Nett JE, Marchillo K, Spiegel CA, Andes DR. 2010. Development and validation of an in vivo Candida albicans biofilm denture model. Infect. Immun. 78:3650-3659. http://dx.doi.org/10.1128/IAI.00480-10.
25. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Jr, Noverr MC. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635-3644. http://dx.doi.org/10.1099/mic.0.039354-0.
26. Khot PD, Suci PA, Miller RL, Nelson RD, Tyler BJ. 2006. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes. Antimicrob. Agents Chemother. 50:3708-3716. http://dx.doi.org/10.1128/AAC.00997-06.
27. LaFleur MD, Kumamoto CA, Lewis K. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50:3839-3846. http://dx.doi.org/10.1128/AAC.00684-06.
28. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340. http://dx.doi.org/10.1128/IAI.71.8.4333-4340.2003.
29. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49: 973-980. http://dx.doi.org/10.1093/jac/dkf049.
30. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780. http://dx.doi.org/10.1128/AAC.46.6.1773-1780.2002.
31. Baillie GS, Douglas LJ. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46:397-403. http://dx.doi.org/10.1093/jac/46.3.397.
32. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, Mohamed S, Ghannoum MA. 2004. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob. Agents Chemother. 48:1727-1732. http://dx.doi.org/10.1128/AAC.48.5.1727-1732.2004.
33. Nobile CJ, Andes DR, Nett JE, Smith FJ, Yue F, Phan QT, Edwards JE, Filler SG, Mitchell AP. 2006. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog. 2:e63. http://dx.doi.org/10.1371/journal.ppat.0020063.
34. Donlan RM. 2001. Biofilm formation: a clinically relevant microbiological process. Clin. Infect. Dis. 33:1387-1392. http://dx.doi.org/10.1086/322972.
35. Douglas LJ. 2002. Medical importance of biofilms in Candida infections. Rev. Iberoam Micol. 19:139-143.
36. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267. http://dx.doi.org/10.1128/CMR.17.2.255-267.2004.
37. Tambyah PA, Halvorson KT, Maki DG. 1999. A prospective study of pathogenesis of catheter-associated urinary tract infections. Mayo Clin. Proc. 74:131-136. http://dx.doi.org/10.4065/74.2.131.
38. Burton DC, Edwards JR, Srinivasan A, Fridkin SK, Gould CV. 2011. Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990-2007. Infect. Control Hosp. Epidemiol. 32:748-756. http://dx.doi.org/10.1086/660872.
39. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team, Participating NHSN Facilities. 2013. Antimicrobialresistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34:1-14. http://dx.doi.org/10.1086/668770.
40. Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Anttila A, Pollock DA, Edwards JR. 2013. National Healthcare Safety Network report, data summary for 2011, device-associated module. Am. J. Infect. Control 41:286-300. http://dx.doi.org/10.1016/j.ajic.2013.01.002.
41. Chandra J, Mukherjee PK, Leidich SD, Faddoul FF, Hoyer LL, Douglas LJ, Ghannoum MA. 2001. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 80:903-908. http://dx.doi.org/10.1177/00220345010800031101.
42. Hawser SP, Douglas LJ. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39:2128-2131. http://dx.doi.org/10.1128/AAC.39.9.2128.
43. Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, Van-Handel M, Andes D. 2007. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520. http://dx.doi.org/10.1128/AAC.01056-06.
44. Kumamoto CA. 2005. A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc. Natl. Acad. Sci. U. S. A. 102:5576-5581. http://dx.doi.org/10.1073/pnas.0407097102.
45. Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL. 2003. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47:3657-3659. http://dx.doi.org/10.1128/AAC.47.11.3657-3659.2003.
46. Nobile CJ, Mitchell AP. 2005. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr. Biol. 15:1150-1155. http://dx.doi.org/10.1016/j.cub.2005.05.047.
47. Uppuluri P, Dinakaran H, Thomas DP, Chaturvedi AK, Lopez-Ribot JL. 2009. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J. Clin. Microbiol. 47:4078-4083. http://dx.doi.org/10.1128/JCM.01377-09.
48. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. 2007. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl. Environ. Microbiol. 73:1697-1703. http://dx.doi.org/10.1128/AEM.02439-06.
49. Nett J, Andes D. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr. Opin. Microbiol. 9:340-345. http://dx.doi.org/10.1016/j.mib.2006.06.007.
50. Elwood CN, Lo J, Chou E, Crowe A, Arsovska O, Adomat H, Miyaoka R, Tomlinson-Guns E, Monga M, Chew BH, Lange D. 2013. Understanding urinary conditioning film components on ureteral stents: profiling protein components and evaluating their role in bacterial colonization. Biofouling 29:1115-1122. http://dx.doi.org/10.1080/08927014.2013.829049.
51. Nett JE, Lepak AJ, Marchillo K, Andes DR. 2009. Time course global gene expression analysis of an in vivo Candida biofilm. J. Infect. Dis. 200: 307-313. http://dx.doi.org/10.1086/599838.
52. Kurosaka Y, Ishida Y, Yamamura E, Takase H, Otani T, Kumon H. 2001. A nonsurgical rat model of foreign body-associated urinary tract infection with Pseudomonas aeruginosa. Microbiol. Immunol. 45:9-15. http://dx.doi.org/10.1111/j.1348-0421.2001.tb01268.x.
53. Kadurugamuwa JL, Modi K, Yu J, Francis KP, Purchio T, Contag PR. 2005. Noninvasive biophotonic imaging for monitoring of catheterassociated urinary tract infections and therapy in mice. Infect. Immun. 73:3878-3887. http://dx.doi.org/10.1128/IAI.73.7.3878-3887.2005.
54. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ. 2010. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 78:4166-4175. http://dx.doi.org/10.1128/IAI.00711-10.
55. Wang X, Fries BC. 2011. A murine model for catheter-associated candiduria. J. Med. Microbiol. 60:1523-1529. http://dx.doi.org/10.1099/jmm.0.026294-0.
56. Uppuluri P, Chaturvedi AK, Lopez-Ribot JL. 2009. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 168: 101-109. http://dx.doi.org/10.1007/s11046-009-9205-9.
57. Al-Fattani MA, Douglas LJ. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297. http://dx.doi.org/10.1128/AAC.48.9.3291-3297.2004.
58. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008. http://dx.doi.org/10.1099/jmm.0.46569-0.
59. Siddiq DM, Darouiche RO. 2012. New strategies to prevent catheterassociated urinary tract infections. Nat. Rev. Urol. 9:305-314. http://dx.doi.org/10.1038/nrurol.2012.68.
60. Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, Diaz P, Vasilakos J. 2009. Characterization of mucosal Candida albicans biofilms. PLoS One 4:e7967. http://dx.doi.org/10.1371/journal.pone.0007967.
61. Davis CP, Balish E, Mizutani K, Uehling DT. 1977. Bladder response to Klebsiella infection: a scanning electron microscopy study. Invest. Urol. 15:227-231.
62. Chen YL, Brand A, Morrison EL, Silao FG, Bigol UG, Malbas FF, Jr, Nett JE, Andes DR, Solis NV, Filler SG, Averette A, Heitman J. 2011. Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. Eukaryot. Cell 10:803-819. http://dx.doi.org/10.1128/EC.00310-10.
63. Nett J, Lincoln L, Marchillo K, Andes D. 2007. Beta-1,3 glucan as a test for central venous catheter biofilm infection. J. Infect. Dis. 195:1705-1712. http://dx.doi.org/10.1086/517522.
64. Johnson CC, Yu A, Lee H, Fidel PL, Jr, Noverr MC. 2012. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect. Immun. 80: 1736-1743. http://dx.doi.org/10.1128/IAI.00019-12.
65. Ricicova M, Kucharikova S, Tournu H, Hendrix J, Bujdakova H, Van Eldere J, Lagrou K, Van Dijck P. 2010. Candida albicans biofilm formation in a new in vivo rat model. Microbiology 156:909-919. http://dx.doi.org/10.1099/mic.0.033530-0.